...
首页> 外文期刊>Scandinavian journal of infectious diseases. >Hepatitis C virus transmission, 1988-1991, via blood components from donors subsequently found to be anti-HCV-positive.
【24h】

Hepatitis C virus transmission, 1988-1991, via blood components from donors subsequently found to be anti-HCV-positive.

机译:1988-1991年,丙肝病毒通过供体的血液成分传播,随后被证明是抗HCV阳性。

获取原文
获取原文并翻译 | 示例

摘要

The recipients of blood components, from the first 12 anti-hepatitis C virus (HCV) positive donors identified by blood donor screening, 1985-1991, were traced retrospectively and tested to assess the HCV transmission rate, HCV genotypes and disease severity. Three enzyme-linked immunosorbent assay (ELISA) positive but RIBA-indeterminate and HCV RNA-negative donors did not transmit HCV to their 9 traced recipients. Nine RIBA- and HCV RNA-positive donors had donated blood to 27 now living recipients of whom 16/27 (59%) were viraemic 1-5 years later. Nine recipients had resolved infection, as determined by PCR HCV RNA. Five of these were RIBA-2 positive but HCV RNA-negative and 4 recipients were RIBA-2-indeterminate and HCV RNA-negative. Two recipients negative in all tests had probably received blood before the donor became infected with HCV. The HCV genotype in each case was identical between the donor and the recipient. Of the viraemic recipients, 50% (8/16) were unsuitable for further investigation ortherapy due to their high age and/or underlying severe disease. At most, only 30% (8/27) of the recipients were suitable for further investigation and/or treatment. Two of these were already diagnosed as being infected with HCV before being traced. It is concluded that the benefit of a general tracing of recipients of blood components from HCV-infected donors is doubtful since only a few of them are suitable candidates for treatment. Our results seem to indicate that it is more appropriate to recommend anti-HCV testing to those seeking medical care who have received transfusions or undergone major surgery before 1992, i.e. before anti-HCV-screening was initiated.
机译:追溯追溯到1985-1991年通过献血者筛选确定的前12个抗丙型肝炎病毒(HCV)阳性献血者的血液成分,并进行了评估,以评估HCV传播率,HCV基因型和疾病严重程度。三个酶联免疫吸附试验(ELISA)呈阳性,但RIBA不确定和HCV RNA阴性的供体并未将HCV传递给其9个追踪的接受者。九位RIBA和HCV RNA阳性的献血者已向27位现在活着的接受者献血,其中1-5年后有16/27位(59%)是病毒感染者。如PCR HCV RNA所确定,有9位接受者已解决感染。其中五个是RIBA-2阳性但HCV RNA阴性,而四个接受者是RIBA-2不确定且HCV RNA阴性。在所有测试中均为阴性的两个接受者可能在供者感染HCV之前就已经接受了血液。在每种情况下,供体和受体之间的HCV基因型相同。在病毒学接受者中,有50%(8/16)因年龄高和/或潜在的严重疾病而不适合进一步研究或治疗。最多只有30%(8/27)的接受者适合进一步研究和/或治疗。在追踪之前,其中两个已经被诊断出感染了HCV。结论是,对来自HCV感染供体的血液成分的接受者进行总体追踪的益处令人怀疑,因为其中只有少数是合适的治疗对象。我们的结果似乎表明,向在1992年之前即开始进行抗HCV筛查之前接受过输血或进行了大手术的就医者推荐抗HCV检测更合适。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号